PASG vs. GRTS, CGTX, ATHA, ATRA, CVM, ELUT, PLX, ALVR, TIL, and CDTX
Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Gritstone bio (GRTS), Cognition Therapeutics (CGTX), Athira Pharma (ATHA), Atara Biotherapeutics (ATRA), CEL-SCI (CVM), Elutia (ELUT), Protalix BioTherapeutics (PLX), AlloVir (ALVR), Instil Bio (TIL), and Cidara Therapeutics (CDTX). These companies are all part of the "biological products, except diagnostic" industry.
Gritstone bio (NASDAQ:GRTS) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.
Passage Bio has lower revenue, but higher earnings than Gritstone bio. Passage Bio is trading at a lower price-to-earnings ratio than Gritstone bio, indicating that it is currently the more affordable of the two stocks.
Gritstone bio presently has a consensus price target of $6.33, suggesting a potential upside of 733.33%. Passage Bio has a consensus price target of $9.33, suggesting a potential upside of 646.67%. Given Passage Bio's higher possible upside, equities research analysts clearly believe Gritstone bio is more favorable than Passage Bio.
In the previous week, Gritstone bio had 7 more articles in the media than Passage Bio. MarketBeat recorded 10 mentions for Gritstone bio and 3 mentions for Passage Bio. Passage Bio's average media sentiment score of 1.06 beat Gritstone bio's score of 0.65 indicating that Gritstone bio is being referred to more favorably in the media.
Gritstone bio has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.
Gritstone bio received 92 more outperform votes than Passage Bio when rated by MarketBeat users. Likewise, 69.15% of users gave Gritstone bio an outperform vote while only 66.20% of users gave Passage Bio an outperform vote.
48.5% of Gritstone bio shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 4.6% of Gritstone bio shares are held by insiders. Comparatively, 14.1% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Passage Bio has a net margin of 0.00% compared to Passage Bio's net margin of -847.24%. Gritstone bio's return on equity of -73.12% beat Passage Bio's return on equity.
Summary
Gritstone bio beats Passage Bio on 8 of the 15 factors compared between the two stocks.
Get Passage Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Passage Bio Competitors List
Related Companies and Tools
